肿瘤的酶-前药疗法
被引量：1
Strategies for enzyme-prodrug cancer therapy
摘要
药物在肿瘤部位的低浓度及系统毒性仍是干扰肿瘤治疗的因素之一。酶-前药疗法将酶的高效性与前药的低毒性相结合,开辟了肿瘤治疗的新领域。现综述酶-前药疗法的分类、原理、应用现状及前景。
出处
《国外医学（肿瘤学分册）》
2005年第6期413-416,共4页
Foreign Medical Sciences (Cancer Section)
基金
国家863高技术研究发展计划基金资助项目(2001AA215321)
参考文献17
-
1Weyel D, Sedlacek HH, Muller R, et al. Secreted human beta-glucuronidase:a novel tool for gene-directed enzyme prodrug therapy. Gene Ther,2000,7(3):224-231.
-
2Niculescu Duvaz I, Scanlon I, Niculescu Duvaz D, et al. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and - aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. J Med Chem,2004,47(10):2651-2658.
-
3Hamstra DA,Lee KC,Tychewicz JM ,et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther,2004,10(5):916-928.
-
4Okabe S, Arai T, Yamashita H, et al. Adenovirus-mediated prodrugenzyme therapy for CEA-producing colorectal cancer cells. J Cancer Res Clin Oncol,2003,129(6):367-373.
-
5Herman J R, Adler H L, Aguilar Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate:a phase Ⅰ clinical trial. Hum. Gene Ther, 1999,10(7):1239-1249.
-
6Rainov NG, Kramm CM, Banning U, et al. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther, 2000,7(21):1853-1858.
-
7Maddens S, Tiberghien P, Contassot E, et al. Development of a competitive PCR method for in vitro and in vivo quantification of herpes simplex virus thymidine kinase and neomycin resistance-expressing cells used in a clinical trial. J. Hematother. Stem Cell Res, 2000,9(2) :225-236.
-
8Hamstra DA, Rice DJ, Fahmy S, et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther,1999,10(12) :1993-2003.
-
9Kirn D. Clinical research results with dl1520 (Onyx-015) ,a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther,2001,8(2) :89-98.
-
10Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med,2000,6(8):862-863.
同被引文献44
-
1何亮.前药的研究进展[J].世界临床药物,2006,27(1):55-58. 被引量：8
-
2李铭东,吉民.肿瘤活化前药的研究与应用进展[J].药品评价,2006,3(3):206-213. 被引量：1
-
3Stella VJ, Himmelstein KJ. Prodrugs and site-spe- cific drug delivery[J].J Med Chem, 1980, 23(12) : 1275-1282.
-
4Testa B. Prodrugs: bridging pharmacodynamic/ pharmacokinetic gaps [J]. Curr Opin Chem Biol, 2009, 13(3): 338-344.
-
5Ettmayer P, Amidon GL, Clement B, et al. Les- sons learned from marketed and investigational pro- drugs [J]. J Med Chem, 2004, 47(10): 2393- 2404.
-
6Beaumont K, Webster R, Gardner I, et al. Design of ester prodrugs to enhance oral absorption ofpoorly permeable compounds: challenges to the dis- covery scientists[J]. Curr Drug Metab, 2003, 4 (6) : 461-485.
-
7Wu KM. A new classification of prodrugs: regula- tory perspectives[J]. Pharmaceuticals, 2009, 2 (3):77-81.
-
8Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications[J].Nat Rev Drug Discov, 2008, 7(3) : 255-270.
-
9Testa B. Prodrug research: futile or fertile[J]. Bio- chem Pharmacol, 2004, 68(11): 2097-2106.
-
10Cundy KC, Sastry S, Luo W, et al. Clinical phar- macokinetics of XP13512, a novel transported pro- drug of Gabapentin [J]. J Clin Pharmacol, 2008, 48(12) : 1378-1388.
二级引证文献2
-
1张小兰,王志强,孙建国,彭英,仲云熙,郝琨,张仓,王广基.Combretastatin A4及其磷酸酯二钠在大鼠体内的药代动力学比较研究[J].中国临床药理学与治疗学,2013,18(11):1205-1210.
-
2肖亚楠,孙建国,万萍,王广基.左旋奥硝唑及磷酸左奥硝唑酯二钠在大鼠体内药代动力学比较研究[J].中国药科大学学报,2014,45(5):571-575. 被引量：2
-
1肖建,曹透峰.5-氟尿嘧啶及其药物前体在胃肠道肿瘤化疗中的应用[J].临床消化病杂志,2008,20(2):125-127. 被引量：4
-
2茅亚红,韩克.三氧化二砷治疗卵巢癌研究进展[J].中医药信息,2009,26(2):18-20.
-
3付相建,杨光华.FOLFOX4方案治疗晚期大肠癌28例分析[J].中国误诊学杂志,2010,10(31):7755-7755. 被引量：2
-
4李明安,马萍.GP73在肝癌诊断中的研究现状及前景[J].实用医技杂志,2014,21(10):1090-1091.
-
5袁芃,徐兵河.表皮生长因子受体抑制剂在乳腺癌治疗中的研究[J].癌症进展,2005,3(3):212-214. 被引量：1
-
6杨冬华.肝癌的免疫治疗现状及前景[J].中华肝脏病杂志,2003,11(12):757-757. 被引量：8
-
7李鹏,周丁华.高强度聚焦超声在中晚期肝癌综合治疗中的应用现状[J].肿瘤学杂志,2013,19(7):518-522.
-
8黄洁夫.肝移植治疗原发性肝癌的现状及前景[J].肝胆外科杂志,1999,7(3):163-165. 被引量：12
-
9文艺.抗体导向酶一前药疗法在肿瘤治疗中的研究进展[J].医学信息（云南）,1998,11(11):35-36.
-
10涂水平,江石湖,吴裕炘.胃、肠肿瘤凋亡治疗研究的现状及前景[J].中华消化杂志,2000,20(2):119-121. 被引量：8
